PARP1 and ovarian carcinoma: Subsequently, in 2016, rucaparib, a second PARP inhibitor, was authorized for the treatment of patients with advanced-stage ovarian cancers harboring deleterious BRCA1/2 mutations who had received two or more prior lines of chemotherapy.